CSLCSLLY +0.70%73 Receivables Turnover is 2.58 as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $48.70 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 846 Biotechnology companies, CSL ranks worse than 80.02% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CSL's Revenue for the
six
months ended in Dec. 2025 was $8,092 Mil. CSL's average Accounts Receivable for the
six
months ended in Dec. 2025 was $3,142 Mil.
Hence, CSL's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.58.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CSL Receivables Turnover Related Terms
CSL Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CSL's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, CSL's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CSL's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a Receivables Turnover of 2.58 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #677 out of 846 companies in the Biotechnology industry, placing it in the top 80%.
Is CSL's Receivables Turnover too high?
CSL's current Receivables Turnover is 2.58. The Biotechnology industry median Receivables Turnover is 5.29. CSL's value of 2.58 is 51.2% below this industry median. Based on the distribution chart, CSL ranks #677 out of 846 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #677 out of 846 companies for Receivables Turnover. This places CSL in the lower half of its industry. The industry median Receivables Turnover is 5.29. CSL's value of 2.58 is 51.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Receivables Turnover of 2.58 is 51.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CSL and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Receivables Turnover is 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.70, compared to a current price of $20.12 — trading 58.7% below its estimated fair value. The current Receivables Turnover is 2.58 and 51.2% below the Biotechnology industry median of 5.29. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CSL (CSLLY), the current Receivables Turnover is 2.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $20.12 is trading 58.7% below its estimated GF Value™ of $48.70.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Receivables Turnover: 2.58
GF Value™: $48.70 vs. price of $20.12 (58.7% below fair value)
Industry Position: 51.2% below the Biotechnology median (#677 of 846)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
